Skip to main content
. 2022 May 30;12(5):84. doi: 10.1038/s41408-022-00677-7

Fig. 1. Overall survival by prior TKI status: CHRYSALIS trial.

Fig. 1

CI confidence interval, OS overall survival, R/R relapsed or refractory, TKI tyrosine kinase inhibitor.